enGene Holdings Inc. (NASDAQ:ENGN - Get Free Report)'s share price gapped up prior to trading on Monday . The stock had previously closed at $14.85, but opened at $15.49. enGene shares last traded at $15.00, with a volume of 3,243 shares.
Wall Street Analyst Weigh In
A number of analysts have recently weighed in on ENGN shares. UBS Group started coverage on shares of enGene in a report on Thursday, March 28th. They issued a "buy" rating and a $37.00 target price on the stock. Guggenheim initiated coverage on shares of enGene in a research note on Monday, April 15th. They set a "buy" rating and a $34.00 price target for the company. Wells Fargo & Company initiated coverage on shares of enGene in a research note on Monday. They set an "overweight" rating and a $30.00 price target for the company. Leerink Partnrs reaffirmed an "outperform" rating on shares of enGene in a research note on Tuesday, February 20th. Finally, SVB Leerink started coverage on shares of enGene in a research report on Tuesday, February 20th. They issued an "outperform" rating and a $31.00 price objective for the company. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $34.40.
View Our Latest Analysis on ENGN
enGene Stock Performance
The firm's fifty day moving average price is $16.11.
Insider Buying and Selling
In related news, major shareholder De Solidarite Des Travai Fonds sold 47,854 shares of the business's stock in a transaction that occurred on Monday, April 22nd. The shares were sold at an average price of $15.00, for a total transaction of $717,810.00. Following the completion of the transaction, the insider now owns 3,036,153 shares in the company, valued at approximately $45,542,295. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of the company. Vivo Capital LLC acquired a new position in enGene during the 4th quarter valued at approximately $6,264,000. BVF Inc. IL acquired a new position in enGene during the 4th quarter valued at approximately $20,777,000. Omega Fund Management LLC acquired a new position in enGene during the 4th quarter valued at approximately $10,441,000. Finally, Fcpm Iii Services B.V. acquired a new position in enGene during the 4th quarter valued at approximately $80,097,000. Institutional investors own 64.16% of the company's stock.
About enGene
(
Get Free Report)
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
See Also
Before you consider enGene, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and enGene wasn't on the list.
While enGene currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
